highli
pathogen
avian
influenza
hpai
consid
signific
threat
next
influenza
pandem
genet
variabl
viru
make
unpreced
risk
global
spread
new
viru
strain
although
humantohuman
transmiss
viru
rare
phenomenon
challeng
recent
success
transmiss
laboratorygener
mutant
viru
either
insert
mutat
hemagglutinin
ha
gene
pandem
strain
select
viru
strain
five
mutat
result
gener
virus
abl
confer
effici
transmiss
among
ferret
anim
model
close
resembl
human
flu
studi
sinc
viru
shown
case
fatal
rate
around
death
among
total
human
infect
report
august
http
suitabl
measur
novel
strategi
urgent
need
prevent
potenti
threat
caus
virus
diverg
strain
effect
vaccin
would
play
key
role
prevent
dire
predict
note
among
influenza
viru
protein
ha
major
antigen
viral
surfac
serv
import
protein
induc
neutral
antibodi
crossprotect
haspecif
antibodi
could
neutral
infect
hpai
virus
interact
receptor
bind
domain
rbd
block
conform
rearrang
associ
membran
fusion
report
antibodi
viru
ha
protein
mediat
heterosubtyp
neutral
respons
virus
healthi
volunt
expos
anim
vaccin
ha
dna
also
show
higher
neutral
antibodi
respons
andor
better
protect
na
np
dna
vaccin
challeng
homolog
heterolog
virus
triclad
dna
vaccin
encod
ha
clade
elicit
broadli
neutral
antibodi
respons
clade
subclad
protect
mice
heterolog
challeng
therefor
base
strong
abil
induc
neutral
antibodi
protect
ha
consid
primari
target
design
effect
vaccin
viru
infect
ha
protein
homotrim
singlechain
monom
initi
synthes
precursor
polypeptid
cleav
host
proteas
two
subunit
rbd
virus
locat
ntermin
region
cover
amino
acid
residu
around
reassort
viru
compris
four
mutat
ha
three
rbd
seven
gene
segment
pandem
viru
may
preferenti
recogn
humantyp
receptor
transmit
effici
ferret
emphas
import
ha
particularli
rbd
receptor
bind
specif
viru
infect
transmiss
success
laboratorygener
transmiss
mutant
viru
continu
evolv
virus
natur
significantli
increas
possibl
emerg
receptorbind
variant
virus
pandem
potenti
therefor
identif
critic
neutral
domain
cnd
ha
particularli
rbd
great
import
develop
efficaci
safe
vaccin
variant
viru
note
vaccin
design
maintain
suitabl
conform
structur
ha
expect
produc
stronger
immun
respons
fact
reveal
trimer
form
ha
may
significantli
improv
immunogen
monomer
ha
vaccin
mice
influenza
viru
iav
infect
viruslik
particl
vaccin
elicit
crossreact
neutral
antibodi
preferenti
bind
oligomer
form
influenza
viru
ha
human
previous
shown
recombin
vaccin
cover
fulllength
region
induc
neutral
activ
diverg
strain
influenza
viru
suggest
subunit
ha
protein
play
signific
role
viru
infect
serv
attract
target
vaccin
develop
howev
design
effect
safe
vaccin
essenti
identifi
critic
neutral
domain
especi
rbd
ha
protein
exampl
design
highli
effect
safe
vaccin
sever
acut
respiratori
syndrom
sar
coronaviru
sarscov
use
critic
neutral
domain
rbd
viral
spike
protein
class
fusion
glycoprotein
similar
ha
influenza
viru
shown
efficaci
sar
viru
infect
therefor
carri
initi
studi
construct
seri
truncat
fragment
cover
differ
length
viru
includ
fulllength
partiallength
rbd
rbd
contain
foldon
fd
trimer
motif
fc
human
igg
ctermini
order
identifi
cnd
induc
neutral
antibodi
use
identifi
cnd
without
fd
fc
construct
seri
new
recombin
differ
conform
purpos
identifi
appropri
conform
cnd
induc
strongest
protect
immun
diverg
strain
viru
studi
construct
six
recombin
protein
cover
differ
length
viru
includ
fulllength
rbd
partiallength
rbd
rbd
contain
fd
fc
ctermini
fig
six
construct
abl
express
solubl
protein
cultur
supernat
transfect
cell
maintain
high
express
strong
puriti
shown
sdspage
fig
express
protein
shown
monom
boil
sampl
line
molecular
weight
shown
nonboil
protein
around
higher
boil
sampl
addit
sampl
buffer
contain
sd
reduc
agent
migrat
gel
presenc
sd
indic
express
protein
fuse
fd
fc
form
suitabl
conform
structur
similar
dimer
reduc
sdspage
fig
addit
western
blot
result
reveal
strong
band
correspond
rel
molecular
weight
recombin
protein
demonstr
protein
recogn
mab
fig
six
truncat
protein
fragment
use
immun
mice
describ
materi
method
sera
collect
day
postlast
vaccin
detect
antibodi
respons
neutral
activ
homolog
viru
shown
fig
protein
fragment
induc
high
igg
antibodi
vaccin
mice
signific
differ
detect
sera
collect
vaccin
group
averag
endpoint
antibodi
titer
detect
sera
mice
vaccin
six
protein
fig
suggest
truncat
protein
fragment
contain
suitabl
conform
high
immunogen
elicit
potent
antibodi
respons
vaccin
mice
neutral
activ
induc
protein
fragment
evalu
collect
mous
sera
homolog
ahha
strain
pseudoviru
indic
fig
vaccin
group
elicit
strong
neutral
antibodi
respons
ahha
pseudoviru
reach
titer
significantli
higher
p
induc
group
vaccin
five
truncat
protein
fragment
includ
residu
region
result
suggest
protein
fragment
contain
residu
cnd
could
induc
strongest
neutral
antibodi
respons
fusion
protein
contain
fd
fc
may
ideal
immunogen
induc
highli
potent
neutral
respons
viru
infect
base
identifi
neutral
region
construct
three
addit
recombin
respect
fuse
fc
fdhi
fig
express
protein
cultur
supernat
cell
follow
character
abil
neutral
ha
fragment
form
differ
conform
structur
ha
shown
sdspage
fig
one
clear
band
observ
nonboil
sampl
molecular
weight
higher
almost
observ
boil
sampl
monom
suggest
mainli
form
dimer
conform
structur
addit
top
band
nonboil
sampl
line
molecular
weight
almost
greater
boil
line
monom
reveal
fuse
fd
mainli
form
trimer
conform
structur
line
protein
similar
band
almost
ident
molecular
weight
detect
boil
nonboil
condit
indic
fragment
alon
maintain
monomer
form
accordingli
particular
band
shown
sdspage
confirm
western
blot
analysi
mab
develop
laboratori
fig
sinc
molecular
weight
shown
reduc
sdspage
would
repres
actual
size
test
protein
next
sought
detect
conform
protein
use
nonreduc
npage
remov
reduc
agent
sampl
run
buffer
indic
fig
clear
band
high
molecular
weight
detect
protein
show
highest
molecular
weight
oligom
clear
band
shown
protein
similarli
band
detect
mab
western
blot
fig
indic
high
specif
protein
comparison
molecular
weight
sampl
without
crosslink
show
molecular
weight
crosslink
sampl
fd
andor
fc
higher
correspond
withoutcrosslink
sampl
molecular
weight
crosslink
almost
withoutcrosslink
fig
result
suggest
identifi
neutral
fragment
fuse
fd
andor
fc
tag
abl
form
conform
structur
dimer
trimer
oligom
evalu
abil
conform
protein
improv
immun
respons
immun
mice
use
purifi
protein
without
fd
andor
fc
compar
igg
antibodi
respons
subtyp
neutral
antibodi
collect
mous
sera
result
shown
fig
b
demonstr
induc
higher
titer
igg
antibodi
ha
protein
induc
highest
titer
igg
antibodi
induc
lowest
antibodi
respons
ha
protein
detect
igg
subtyp
indic
protein
induc
similar
higher
level
elicit
lowest
level
vaccin
mice
fig
howev
pb
control
induc
background
level
igg
antibodi
respons
subtyp
fig
evalu
neutral
activ
protein
vaccin
mous
sera
reveal
protein
fd
andor
fc
abl
induc
significantli
higher
level
neutral
antibodi
homolog
ahha
heterolog
hkha
pseudovirus
specif
induc
highest
lowest
neutral
antibodi
respons
respect
three
strain
elicit
significantli
higher
level
neutral
antibodi
howev
pb
control
induc
neutral
antibodi
test
pseudovirus
fig
neutral
activ
induc
protein
evalu
liveviru
base
neutral
assay
similarli
elicit
highest
lowest
neutral
antibodi
respons
respect
two
live
virus
test
induc
similarli
high
level
neutral
antibodi
pb
control
group
induc
background
level
neutral
antibodi
test
virus
fig
result
suggest
protein
appropri
polymer
conform
structur
capabl
induc
significantli
higher
level
antibodi
respons
crossneutr
activ
monomer
protein
cover
neutral
fragment
viru
infect
demonstr
abil
protein
suitabl
polymer
conform
promot
greater
crossprotect
protein
monom
mice
vaccin
fusion
protein
challeng
clade
clade
virus
day
postlast
vaccin
observ
daili
two
week
surviv
bodi
weight
chang
shown
fig
b
protein
complet
crossprotect
vaccin
mice
viru
challeng
protect
vaccin
mice
challeng
strain
protein
could
protect
vaccin
mice
viru
challeng
compar
protein
fuse
fd
andor
fc
protein
provid
much
lower
protect
rate
mice
pb
control
group
surviv
challeng
two
viru
strain
day
slight
bodi
weight
loss
less
found
day
mice
vaccin
challeng
virus
mice
vaccin
protein
challeng
abl
regain
normal
bodi
weight
addit
mice
vaccin
group
show
slightli
higher
level
bodi
weight
loss
around
day
postchalleng
vaccin
group
challeng
viru
contrast
mice
vaccin
demonstr
signific
loss
bodi
weight
particularli
day
respect
challeng
viru
strain
howev
mice
pb
control
group
indic
obviou
continu
decreas
bodi
weight
day
reach
sever
weight
loss
day
postchalleng
fig
mice
lost
greater
initi
bodi
weight
human
euthan
result
suggest
protein
suitabl
polymer
conform
particularli
one
fuse
fd
fc
could
significantli
protect
vaccin
mice
variou
viru
challeng
crossprotect
effect
induc
protein
fuse
without
fd
andor
fc
evalu
detect
viral
titer
lung
tissu
vaccin
mice
challeng
viru
shown
fig
significantli
lower
level
viru
titer
detect
mice
vaccin
protein
vaccin
protein
challeng
virus
p
howev
viru
titer
pb
control
group
still
significantli
higher
vaccin
group
result
suggest
protein
suitabl
polymer
conform
addit
fd
andor
fc
induc
strong
crossprotect
diverg
viru
challeng
hapi
viru
continu
cross
speci
barrier
frequent
infect
human
sinc
confirm
human
case
report
http
although
abil
gener
highli
transmiss
form
laboratori
enabl
investig
elucid
mechan
viru
transmiss
advanc
pose
consider
threat
public
health
rais
concern
issu
biosafeti
dualus
research
thu
search
readili
avail
effect
vaccin
justifi
prevent
season
epidem
prepar
unpredict
viru
infect
current
varieti
vaccin
develop
specif
target
viru
form
inactiv
viru
live
viru
dna
viral
vectorbas
vaccin
shown
efficaci
viru
infect
preclin
clinic
trial
report
demonstr
vaccin
drift
variant
avian
ha
protein
elicit
broaden
antibodi
respons
protect
challeng
homolog
drift
live
influenza
viru
consensushabas
dna
vaccin
also
seen
protect
mice
diverg
influenza
virus
addit
live
attenu
modifi
vaccinia
ankara
mva
vector
vaccin
express
influenza
ha
induc
substanti
crossclad
protect
immun
vaccin
anim
vero
cellderiv
whole
viru
clade
influenza
vaccin
phase
iii
studi
safeti
immunogen
test
healthi
adult
hong
kong
singapor
show
high
toler
immunogen
two
vaccin
induct
crossneutr
antibodi
respons
nevertheless
continu
frequent
mutat
viru
particularli
viral
ha
protein
current
avail
vaccin
face
signific
efficaci
challeng
new
viru
strain
make
extrem
import
identifi
critic
neutral
region
util
target
develop
effect
safe
vaccin
everchang
diverg
viru
strain
receptor
bind
fusion
protein
ha
influenza
viru
play
import
role
initi
viral
infect
receptorbind
domain
ha
determin
speci
sialic
acid
receptor
linkag
ha
particularli
subunit
main
region
induct
neutral
activ
influenza
viru
infect
use
develop
subunit
influenza
vaccin
inde
previous
demonstr
recombin
protein
contain
fulllength
could
elicit
neutral
antibodi
respons
immun
mice
confirm
subunit
contain
import
neutral
epitop
howev
recent
studi
develop
sar
vaccin
rais
seriou
concern
safeti
use
fulllength
protein
sarscov
vaccin
sinc
nonneutr
region
protein
could
induc
harm
immun
respons
vaccin
anim
therefor
essenti
identifi
cnd
design
effect
influenza
vaccin
contain
major
neutral
domain
therefor
construct
six
truncat
recombin
fragment
cover
partial
fulllength
rbd
region
fig
immun
mice
although
six
truncat
protein
fragment
abl
induc
strong
antibodi
vaccin
mice
one
contain
residu
cover
fulllength
rbd
induc
significantli
higher
level
neutral
antibodi
pseudotyp
viru
fragment
fig
suggest
fragment
contain
cnd
comparison
amino
acid
sequenc
identifi
cnd
reveal
high
similar
among
hundr
strain
caus
human
avian
diseas
data
shown
suggest
identifi
cnd
high
potenti
develop
univers
candid
vaccin
particularli
nativ
influenza
ha
protein
polymer
trimer
seem
recombin
ha
fragment
easili
form
function
conform
trimer
oligomer
structur
format
function
molecul
ha
may
introduc
addit
extran
sequenc
trimer
ha
could
form
fuse
ha
trimer
heptad
repeat
sequenc
deriv
wildtyp
dimer
repeat
found
saccharomyc
cerevisia
fd
sequenc
ctermin
domain
fibritin
often
appli
artifici
trimer
domain
thu
requir
form
fibritin
trimer
structur
recombin
protein
conjug
motif
shown
form
stabl
trimer
improv
antivir
activ
fc
util
anoth
motif
promot
oligomer
conform
express
protein
purpos
increas
immunogen
recombin
protein
therefor
construct
three
addit
recombin
protein
base
identifi
neutral
region
fuse
fd
fc
fuse
ha
fragment
fdhi
fc
respect
conform
protein
subsequ
evalu
expect
protein
fd
fc
abl
form
oligomer
structur
highest
molecular
weight
fuse
fc
fdhi
form
differ
polymer
conform
includ
dimer
trimer
rel
lower
molecular
weight
howev
protein
without
fusion
fd
fc
form
polymer
conform
structur
remain
monomer
form
fig
thu
result
emphas
import
ad
foreign
motif
promot
oligomer
ha
believ
protein
capabl
maintain
nativ
trimer
oligomer
structur
ha
would
like
induc
stronger
immun
respons
monom
determin
conform
structur
cover
identifi
critic
neutral
region
enhanc
immun
respons
crossprotect
immun
first
immun
mice
use
fusion
protein
compar
antibodi
respons
neutral
antibodi
addit
evalu
crossprotect
two
differ
strain
viru
cell
cultur
vitro
mous
model
vivo
found
protein
highest
molecular
weight
oligom
induc
strongest
neutral
antibodi
respons
crossprotect
challeng
two
test
strain
includ
clade
clade
follow
lower
molecular
weight
polym
mainli
dimer
mainli
trimer
monomer
protein
induc
much
lower
level
neutral
antibodi
respons
protect
protein
fuse
fd
andor
fc
fig
data
indic
trimer
protein
may
elicit
stronger
protect
monom
oligomer
fd
fc
promot
protect
fc
fragment
immunogen
enhanc
immunogen
possibl
prolong
halflif
immunogen
interact
fc
receptor
fcr
antigen
present
cell
apc
immunogen
fd
fc
form
oligom
higher
molecular
weight
dimer
form
therefor
may
even
longer
halflif
thu
demonstr
stronger
effect
induct
immun
respons
note
neither
fc
alon
fd
alon
abl
induc
haspecif
antibodi
respons
none
express
ha
protein
induc
antibodi
respons
season
influenza
virus
includ
data
shown
confirm
high
specif
recombin
protein
ha
result
demonstr
influenza
haspecif
protein
polymer
conform
structur
may
significantli
enhanc
crossprotect
immun
diverg
strain
influenza
viru
infect
summari
identifi
cnd
contain
rbd
viru
addit
fd
fc
cnd
result
format
oligomer
conform
could
induc
highli
potent
neutral
antibodi
respons
crossprotect
two
test
strain
cover
clade
clade
respect
result
suggest
identifi
cnd
optim
conform
great
potenti
develop
effect
safe
influenza
vaccin
prevent
infect
similar
strategi
use
design
vaccin
emerg
reemerg
viral
pathogen
class
glycoprotein
anim
studi
carri
strict
accord
recommend
guid
care
use
laboratori
anim
nation
institut
health
state
key
laboratori
pathogen
biosecur
beij
institut
microbiolog
epidemiolog
protocol
approv
committe
ethic
anim
experi
new
york
blood
center
permit
number
experi
relat
influenza
virus
perform
approv
biosafeti
level
laboratori
anim
facil
beij
institut
microbiolog
epidemiolog
china
permit
number
construct
express
purif
recombin
ha
protein
done
previous
describ
briefli
gene
encod
truncat
access
fd
amplifi
pcr
use
recombin
plasmid
fuse
fd
fc
templat
histidin
tag
ad
ctermini
respect
easi
purif
protein
amplifi
gene
fragment
digest
ecor
bgl
ii
restrict
enzym
insert
express
vector
hereinaft
name
fc
invivogen
san
diego
ca
plasmid
encod
residu
fc
construct
insert
digest
fragment
directli
fc
vector
recombin
plasmid
transfect
cell
atcc
manassa
va
seed
h
transfect
cultur
medium
replac
serumfre
dmem
invitrogen
carlsbad
ca
h
later
supernat
contain
express
protein
collect
h
posttransfect
recombin
protein
purifi
protein
affin
chromatographi
ge
healthcar
piscataway
nj
protein
fc
ninta
superflow
qiagen
valencia
ca
protein
tag
accord
manufactur
instruct
construct
recombin
fragment
illustr
fig
purifi
protein
first
analyz
sdspage
western
blot
previous
describ
briefli
protein
either
nonboil
boil
min
separ
tricin
gel
invitrogen
stain
coomassi
blue
transfer
nitrocellulos
membran
western
blot
analysi
block
nonfat
milk
pbst
overnight
blot
incub
mab
develop
laboratori
h
room
temperatur
three
wash
blot
incub
horseradish
peroxidas
hrp
conjug
goat
antimous
igg
invitrogen
h
room
temperatur
signal
visual
ecl
western
blot
substrat
reagent
amersham
hyperfilm
ge
healthcar
npage
analysi
protein
first
separ
npage
gel
use
npage
sampl
buffer
run
buffer
invitrogen
follow
protocol
protein
crosslink
detect
purifi
protein
mix
glutaraldehyd
final
concentr
mm
left
room
temperatur
dark
h
sdspage
coomassi
blue
stain
describ
four
sixweekold
femal
balbc
mice
primevaccin
subcutan
sc
recombin
ha
protein
fragment
formul
montanid
isa
adjuv
seppic
fairfield
nj
boost
twice
immunogen
adjuv
interv
control
mice
sc
inject
volum
pb
adjuv
sera
collect
day
postlast
vaccin
detect
haspecif
igg
antibodi
subtyp
neutral
antibodi
collect
mous
sera
analyz
haspecif
antibodi
respons
elisa
describ
previous
briefli
elisa
plate
respect
precoat
truncat
protein
fragment
fulllength
ha
protein
eenzym
gaithersburg
md
overnight
block
nonfat
milk
h
serial
dilut
mous
sera
ad
plate
incub
h
follow
four
wash
bound
antibodi
incub
hrpconjug
goat
antimous
igg
invitrogen
antimous
bethyl
laboratori
montgomeri
tx
antimous
invitrogen
h
reaction
visual
substrat
tmb
invitrogen
stop
absorb
nm
measur
elisa
plate
reader
tecan
san
jose
ca
neutral
activ
collect
mous
sera
perform
use
establish
pseudoviru
neutral
assay
previous
describ
briefli
cell
cotransfect
plasmid
encod
envdefect
luciferaseexpress
genom
plasmid
encod
ha
homolog
ahha
clade
heterolog
contain
hkha
clade
clade
exogen
bacteri
neuraminidas
na
sigma
st
loui
mo
ad
h
later
supernat
harvest
h
posttransfect
singlecycl
infect
pseudoviruscontain
supernat
incub
serial
dilut
mous
sera
h
ad
cell
fresh
medium
ad
h
later
cultur
continu
h
cell
lyse
cell
lysi
buffer
promega
madison
wi
transfer
luminomet
plate
luciferas
substrat
promega
ad
rel
luciferas
activ
determin
ultra
luminomet
tecan
neutral
ha
pseudoviru
calcul
present
neutral
antibodi
titer
mous
sera
detect
live
virusbas
neutral
assay
previous
describ
modif
briefli
serial
dilut
mous
sera
incub
influenza
viru
contain
clade
clade
h
prior
addit
monolay
madindarbi
canin
kidney
mdck
cell
viru
supernat
remov
replac
fresh
medium
virusinfect
cell
incub
h
infect
identifi
presenc
cytopath
effect
cpe
day
titer
calcul
reedmuench
method
five
group
femal
balbc
mice
respect
sc
vaccin
recombin
protein
contain
fuse
fc
fd
fd
plu
fc
without
fd
fc
plu
adjuv
boost
twice
interv
vaccin
mice
intranas
infect
lethal
dose
clade
clade
viru
respect
day
postlast
vaccin
infect
mice
observ
daili
day
clinic
sign
includ
bodi
weight
loss
surviv
rate
accordingli
calcul
mice
lost
greater
bodi
weight
euthan
five
mice
per
group
sacrif
day
postchalleng
lung
sampl
collect
virolog
analysi
vaccin
infect
euthanasia
procedur
perform
anesthesia
isofluran
lung
tissu
harvest
perform
mice
euthan
viru
titer
detect
previous
describ
briefli
lung
tissu
euthan
mice
asept
remov
homogen
minim
essenti
medium
mem
plu
antibiot
achiev
wv
suspens
lung
cell
cultur
plate
tenfold
serial
dilut
sampl
ad
monolay
mdck
cell
quadrupl
allow
absorb
h
presenc
supernat
remov
replac
mem
plu
antibiot
mdck
cell
incub
h
viral
cpe
observ
daili
viru
titer
determin
ha
test
ha
test
turkey
red
blood
cell
lampir
biolog
laboratori
pipersvil
pa
ad
cell
cultur
supernat
incub
room
temperatur
min
well
contain
ha
score
posit
viru
titer
calcul
reed
muench
method
express
lung
tissu
valu
present
mean
sd
statist
signific
among
differ
group
calcul
student
test
use
stata
statist
softwar
p
valu
less
consid
signific
